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Abstract
Unresectable pancreatic cancer has a dismal prognosis
with a median survival of 3–5 months in untreated dis-
ease. Since the introduction of gemcitabine, pancreatic
cancer may no longer be regarded a chemotherapy-
resistant tumor. Treatment with single-agent gemcita-
bine achieved clinical benefit and symptoms improve-
ment in 20–30% of patients. While 1-year survival was
observed in 2% of 5-fluorouracil (5-FU)-treated patients,
it was raised to 18% by single-agent gemcitabine. Good
treatment tolerability and low incidence of side effects
are clear advantages of single-agent gemcitabine. Im-
provement of efficacy is, however, expected from combi-
nation treatment. Gemcitabine and cisplatin given as
first-line treatment in three studies achieved a median
survival of 7.4–8.3 months. One-year survival was raised
to 28% as reported in one study. Comparable activity
was obtained by a combination of gemcitabine with 5-
FU. Nine studies using gemcitabine in combination with
standard-dose or high-dose 5-FU reported a median sur-
vival ranging from 5.5 to 13 months. Notwithstanding
these promising results, recommendations regarding
palliative chemotherapy of pancreatic cancer remain ten-
tative and still need confirmation by presently ongoing
phase III trials. Inclusion of pancreatic cancer patients
into clinical trials should be a major goal. Outside clinical
trials, patients should present with an adequate PS (Kar-
nofsky-performance index 670) to qualify for chemo-
therapy.
Copyright © 2001 S. Karger AG, Basel
Introduction
The incidence of pancreatic cancer has risen in recent
decades. Cancer of the pancreas currently ranges between
the fourth and the fifth leading cause of cancer mortality
[1, 2]. The disease primarily involves an older population
with a peak incidence in the sixth decade. Tumors pre-
dominantly evolve from the exocrine pancreas and repre-
sent adenocarcinomas in 95% of cases.
The inherent dilemma of pancreatic carcinoma con-
sists in an early systemic spread and a late diagnosis. Most
of patients (85–90%) are diagnosed at an advanced stage
when curative surgery is no longer possible. Thus, the
great majority of patients will eventually succumb to met-
astatic disease, with a median survival of 3–6 months [3].
Given this situation, an improvement of prognosis may
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only be expected from an optimization of systemic treat-
ment.
Response to chemotherapy is greatly dependent on the
performance status (PS) of the patient. A Karnofsky PS
670 was associated with a survival time more than 2-fold
longer (5.5 months) than that in patients with lower PS
values (2.4 months) [4]. Disease stage is another impor-
tant prognostic parameter [4], as patients with locally
advanced tumors demonstrated a longer median survival
(6.6 months) compared to that of patients with metastatic
disease (4.4 months). Therefore, the relative risks and
potential benefits of systemic chemotherapy should be
weighed in each situation to ensure that patients and phy-
sicians have realistic expectations regarding treatment.
Evaluation of Response in Pancreatic Cancer
Even modern imaging techniques, such as computed
tomography (CT) or magnetic resonance imaging (MRI),
frequently do not allow accurate localization and mea-
surement of tumor extension within the adjacent tissues
[2]. This is partly explained by the retroperitoneal local-
ization of pancreatic tumors. Additionally, desmoplastic
and local inflammatory reactions induced by the tumor
make it difficult to differentiate between tumor and nor-
mal surrounding tissue. Differences in response between
metastatic lesions and primary tumor may be explained
on grounds of variable desmoplastic reactions. Tumor
response may be underestimated because reactive fibrous
tissue does not readily shrink during successful chemo-
therapy. By contrast, inflammatory reactions may be
reduced more rapidly causing an overestimation of tumor
response [5].
Consequently, there is not only a problem of tumor
size definition at the time of diagnosis, but also a fre-
quently inadequate estimation of tumor response when
chemotherapy has been applied [6]. Conventional end-
points such as tumor response may therefore be inade-
quate tools for the evaluation of pancreatic cancer treat-
ment.
Endpoints of Palliative Chemotherapy in
Pancreatic Cancer
Because tumor response occurs late during treatment
and may be obscured by diagnostic uncertainties, new
endpoints have to be determined. Stabilization of disease
should be accepted as the primary goal of palliative treat-
ment, which can best be expressed by the combined evalu-
ation of complete response (CR) + partial response (PR) +
stable disease (SD). Even patients with SD respond to
treatment and may ultimately profit from it by prolonged
survival.
The determination of 1-year survival in addition to
median survival appears to be a useful tool to characterize
those patients who show a prolonged treatment benefit.
Because there is a large amount of poorly responding pan-
creatic cancer patients, 1-year survival provides superior
information about the responding minority.
Analysis of Clinical Benefit Response as a
Surrogate Parameter for Response
A reduction of quality-of-life symptoms has gained
increasing interest as a surrogate parameter of tumor
response [5]. Specific attention has been given to the
reduction of pain and analgesic consumption. Tumor-
associated pain caused by irritation of the splanchnic
nerve is a leading symptom of pancreatic cancer (80% at
first diagnosis). Clinical experience shows that small re-
ductions of tumor size, objectively corresponding to SD,
may often cause a major improvement of pain. Ameliora-
tion of tumor-associated pain often precedes the measur-
able reduction of tumor size and consequently serves as
an early predictor of therapeutic efficacy [7]. 
Consequently, a number of studies have analyzed ‘clin-
ical benefit response’ as a composite parameter of clinical
efficacy [8, 9]. Two primary measures were evaluated: the
first measure consisted of the parameters, PS and pain;
the latter being composed of pain intensity and analgesic
consumption. The course of the patient’s body weight was
analyzed as a second measure. Clinical benefit response
was then primarily evaluated using the parameters of pain
and PS. Weight gain was additionally used only if a
patient was considered stable by primary measures. A
positive response of clinical benefit was established when
a significant improvement from baseline of the respective
measures was observed for an interval of at least 4 weeks:
pain intensity ^50%, analgesic consumption ^50%, im-
provement of Karnofsky PS by 620 points, or weight
gain 67% [9]. 
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Table 1. 5-Fluorouracil: efficacy in three
independent randomized trials Reference 5-FU regimen n/eval PR, % SD, % Survival
months
1-year
survival, %
500 mg/m2, d 1–5
q 5 weeks
64/41 7 NA 3.5 NA
8 600 mg/m2, weekly 63/57 0 19 4.41 2
15 500 mg/m2, d 1–5
q 4 weeks
103/97 0 13.4 NA 9
n/eval = Recruited/evaluable patients; 5-FU = 5-fluorouracil; PR = partial remission;
SD = stable disease; NA = not available.
Tumor Marker CA 19-9: A Parameter of Tumor
Response
In view of everyday decision making, analysis of surro-
gate constructs like quality of life (QOL), symptoms
reduction, or clinical benefit are time consuming and fre-
quently lack objectivity. Alternatively, determination of
tumor marker kinetics may provide simple, fast, and reli-
able information on therapeutic efficacy.
The prognostic importance of CA19-9 has already
been demonstrated for neoadjuvant treatment of operable
pancreatic cancer [10–13]. Due to the rather low activity
of chemotherapy, data have remained scarce regarding
the impact of CA19-9 kinetics during palliative treat-
ment. In a study using gemcitabine and cisplatin for pal-
liative treatment, 20 of 21 evaluable patients presented
with elevated tumor markers. All patients responding to
chemotherapy with a CR or PR (8/21) demonstrated a
fast and lasting reduction of CA19-9. Although the de-
cline of CA19-9 was observed after the first treatment
cycle, remissions were documented by imaging proce-
dures only after a median of five chemotherapy courses.
However, only patients reaching CR (4/21) achieved nor-
malization of CA19-9 levels. In patients where SD was
determined by imaging techniques, CA19-9 declined in
all but one patient (7/8), demonstrating the biochemical
efficacy of treatment without significant reduction of
tumor volume. These data indicate that determination of
CA19-9 may provide additional reliable evidence of re-
sponse, however, a prospective, randomized trial is neces-
sary before it is clear that CA19-9 could help guide clinical
decision making and ultimately reduce the number of
imaging procedures necessary. Its role in the majority of
patients with pancreatic cancer who do not have an objec-
tive response to therapy, but rather may experience pallia-
tion of symptoms, also remains unclear [14].
Palliative Chemotherapy: Single-Agent and
Combination Regimens
Since curative therapeutic approaches are not avail-
able, therapeutic efforts in tumor stages III and IV are
mainly directed towards palliation. In the past, pancreatic
cancer was rightfully considered a chemo- and radio-resis-
tant tumor. A recent analysis of 28 phase II trials (1991–
1994) analyzing the efficacy of 25 different agents demon-
strated a median objective response rate (RR) of 0%
(range 0–14.3%), while median survival in 19 evaluable
studies amounted to 3 months (range 2–8.3 months) [5].
Thus, based on these data, the benefit of chemotherapy as
an instrument for disease palliation is clearly questiona-
ble.
Accordingly, a generally accepted chemotherapy regi-
men had not been defined for pancreatic cancer. 5-Fluo-
rouracil (5-FU) was frequently the drug of choice when
single-agent chemotherapy was used in selected patients.
While high RRs in the range of 15–20% were reported in
the 1970–1980s, more recent analyses, performed in the
1990s, confirmed a median response rate of only 0–14%.
The true importance of 5-FU treatment may be demon-
strated more adequately by an analysis of three random-
ized studies (table 1). Taken together, 207 patients re-
ceived either single-agent 5-FU [8, 15] or 5-FU/folinic
acid [16]. While two studies reported an RR of 0% [8, 15],
the other [16] showed a response in 7% of patients, yield-
ing a mean remission rate for the three studies of 2.3%. In
two evaluable studies, median survival was 3.5 and 4.65
months, respectively, and clearly did not exceed the sur-
vival expected with best supportive care alone [8, 16].
New agents, such as paclitaxel, docetaxel, irinotecan,
topotecan, and oxaliplatin, have been tested in pancreatic
cancer, but have not gained clinical importance so far.
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Table 2. Studies of gemcitabine single-agent activity in pancreatic carcinoma
Reference Phase n/eval Treatment Gemcitabine
dose, mg/m2
PR
n (%)
SD
n (%)
PR + SD
%
Clinical benefit
response
eval/n (%)
Survival
months
II 44/35 1st-line 800 5 (14.3) 14 (40.0) 54.3 NA 5.6
18 II 34/32 1st-line 800 2 (6.3) 6 (18.8) 25.1 NA 6.3
8 III 63/56 1st-line 1,000 3 (5.4) 22 (39.3) 44.7 15/63 (23.8) 5.7
9 II 63/57 5-FU-
refractory
1,000 6 (10.5) 17 (29.8) 40.3 17/63 (27.0) 3.9
n/eval = Recruited/evaluable patients; 5-FU = 5-fluorouracil; PR = partial remission; SD = stable disease; NA = not available.
Combination regimens like FAM (5-FU, doxorubicin,
mitomycin C) or SMF (streptozotocin, mitomycin C, 5-
FU) have induced higher RRs at the expense of greater
toxicity. A prolongation of survival compared to that of
single-agent 5-FU was, however, not achieved in random-
ized studies [3, 16].
Single-Agent Activity of Gemcitabine in
Advanced Pancreatic Cancer
Gemcitabine is a pyrimidine antimetabolite [17] with
good activity in various solid tumors and is presently rec-
ommended as a first-line treatment in pancreatic cancer.
The typical phase II regimen of single-agent use includes a
dose of 1,000–1,200 mg/m2 given as a 30-min i.v. infusion
on days 1, 8, and 15 of a 28-day cycle [3]. Gemcitabine is
characterized by a low profile of side effects and accord-
ingly by an excellent clinical tolerability. 
Currently, four studies – one randomized, pivotal
phase III study [8] and three phase II studies [9, 18, 19] –
are available demonstrating the clinical activity of gemci-
tabine in pancreatic cancer (table 2). A consequent analy-
sis of clinical benefit response was performed in two stud-
ies [8, 9]. Only those patients with the following were
included: a Karnofsky PS !80, a pain intensity score 620
mm (of a possible 100 mm according to the Memorial
Pain Assessment Card), or a baseline analgesic consump-
tion of 610 mg morphine equivalent per day. The follow-
ing conclusions may be drawn from the summary of the
results of these two studies. A clinical benefit response
was observed in 24 and 27%, respectively, of gemcita-
bine-treated patients [8, 9] and exceeded the clinical bene-
fit of 5-FU treatment (4.8%) as observed in the random-
ized study (p = 0.0022) [8]. Accordingly, the median sur-
vival of gemcitabine-treated patients was also significant-
ly longer than that of the 5-FU-treated patients (p =
0.0025). After a follow-up of 1 year, 18% of gemcitabine-
treated patients survived compared to 2% of 5-FU-
treated patients [8]. With a PR rate of 5.4–14.3%, the
objective response may be considered moderate. If, how-
ever, SD and PR are taken together as an acceptable goal
of palliative treatment, the objective rate of disease stabi-
lization (25.1–54.3%) fits the results of the clinical benefit
response evaluation much better.
Within an investigational new drug treatment program
analyzing 3,023 pancreatic cancer patients treated with
single-agent gemcitabine, a prospective evaluation of dis-
ease-related symptoms improvement yielded a cumula-
tive rate of 18.4% after the fourth treatment cycle. In 982
evaluable patients, an overall RR of 12% (95% confi-
dence interval [CI], 10.0–14.0%) was noted. For 2,380
patients with evaluable survival data, median survival
was 4.8 months (95% CI, 4.5–5.1 months) with a 1-year
survival of 15% [4].
High-Dose Gemcitabine and Prolonged Drug
Application
While a gemcitabine dose of 1,000–1,200 mg/m2 ap-
plied as a 30-min infusion has become a widely accepted
standard for single-agent treatment, the optimal dose has
not been defined so far. Fossella et al. [20] performed a
phase I study in first-line non-small cell lung cancer
(NSCLC) patients evaluating gemcitabine doses ranging
from 1,000–2800 mg/m2. In this patient entity, a maxi-
mum tolerated dose of 2,200 mg/m2/week for 3 weeks
every 4 weeks was reported.
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Table 3. Gemcitabine plus cisplatin
combination treatment in phase II studies Reference n/eval Regimen OR, % SD, % Survival
months
41/35 Gemcitabine 1,000 mg/m2, d 1, 8, 15
Cisplatin 50 mg/m2, d 1, 15, q d 29
11.4 57.1 8.3
29 52/32 Gemcitabine 1,000 mg/m2, wkly ! 7
Cisplatin 25 mg/m2, wk 1–3 and 5–7,
then 1 wk rest, then d 1, 8, 15 q d 29
31 NA NA
28 27/22 Gemcitabine 1,000 mg/m2, d 1, 8, 15
Cisplatin 50 mg/m2, d 1, 15, q d 29
36.4 27.3 7.4
38 49/43 Gemcitabine 600 mg/m2, d 1 + 8
Cisplatin 40 mg/m2, d 1
Epirubicin 40 mg/m2, d 1
5-FU CI 200 mg/m2, d 1–28, q 4 weeks
58 33 9.4+
n/eval = Recruited/evaluable patients; 5-FU = 5-fluorouracil; OR = overall remission;
SD = stable disease; NA = not available; CI = continuous infusion.
Pur et al. [21] undertook a phase II study in metastatic
pancreatic cancer patients applying gemcitabine at the
increased dose of 2,200 mg/m2 every 2 weeks. In 39 evalu-
able patients, a PR rate of 22.5%, an SD rate of 40%, and
a median survival of 7.3 months were reported. Clinical
benefit was observed in 37% (11/30) of patients. These
data would argue for a dose increase of gemcitabine,
because comparable treatment results have not been
achieved with standard doses in the range of 800–1,000
mg/m2 (table 2).
However, these data need to be discussed in the con-
text of the results of the following randomized phase II
trial of dose-intense gemcitabine by Tempero et al. [22].
In the standard infusion arm (A), gemcitabine was admin-
istered to 37 patients with metastatic disease at a dose of
2,200 mg/m2 (30-min. i.v. infusion) weekly times three
every 4 weeks. While dose intensity was greater in this
trial, the RR was only 2.7% with a median survival of 4.7
months and a 1-year survival of 0%. These results are not
only in striking contrast to the results published by Pur et
al., they also do not fit into the context of the data so far
reported for single-agent gemcitabine as shown in table 2.
The comparator arm (B) of this trial investigated the effi-
cacy of a fixed gemcitabine dose rate of 10 mg/m2 per
minute. This dose rate was chosen because previous stud-
ies had demonstrated saturation of the activating enzyme
deoxycytidine kinase. Thirty patients received 1,500 mg/
m2 as a 150-min infusion. This schedule resulted in an RR
of 16.6%, a median survival of 6.1 months, and a 1-year
survival of 23%. The promising activity achieved with the
fixed dose rate in arm B seems to support the underlying
pharmacologic mechanism; however, the need for confir-
matory phase III trials is clearly needed, and no definitive
conclusions may be drawn at the present time.
Combination Therapy with Gemcitabine and
Cisplatin
Preclinical studies have demonstrated that gemcita-
bine acts as an effective inhibitor of DNA repair [23]. In
fact, synergistic cytotoxicity was observed under condi-
tions where gemcitabine inhibited adequate repair of
DNA damage caused by cisplatin or radiation [24, 25].
While cisplatin alone has some activity in pancreatic can-
cer and induced a remission rate of 21% in one phase II
study, median survival was not extended beyond 4.0
months [26]
Therefore, a phase II study was initiated to determine
the impact of gemcitabine/cisplatin combination treat-
ment on clinical efficacy and quality of life in pancreatic
cancer patients [27]. A total of 41 patients received gemci-
tabine at a dose of 1,000 mg/m2 (days 1, 8, and 15) and
cisplatin at a dose of 50 mg/m2 (days 1 and 15), every 29
days. In 35 evaluable patients, an overall RR of 11.5%
(95% CI, 3.2–26.7%) was observed that was accompanied
by disease stabilization (63 months) in 57.1% of patients.
In other words, this regimen achieved at least a transient
stabilization of disease (CR + PR + SD) in 69% of
patients. Median survival was 8.3 months and appears
superior to the 3–5 months expected in patients receiving
best supportive care alone. After 1 year, 28% of patients
n/eval
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Table 4. Survival of pancreatic cancer patients in relation to first-line treatment
Reference 15
5-FU/Cisplatin
Phase III
8
Gemcitabine
Phase III
7
Gemcitabine/5-FU
Phase II
27
Gemcitabine/Cisplatin
Phase II
104/94 63/56 54/54 41/35
Regimen 5-FU 1,000 mg/m2
CI 24 h, d 1–5, q d 29
Cisplatin 100 mg/m2, d 1
Gemcitabine 1,000 mg/m2
weekly ! 7, 1 week rest
then d 1, 8, 15, q d 29
Gemcitabine 1,000 mg/m2
5-FU 600 mg/m2 bolus
d 1, 8, 15, q d 29
Gemcitabine 1,000 mg/m2
d 1, 8, 15, q d 29
Cisplatin 50 mg/m2, d 1, 15
Median survival, months NA 5.7 7.0 8.3
6-month survival, % 38 46 61 69
9-month survival, % NA 24 35 43
12-month survival, % 17 18 22 28
n/eval = Recruited/evaluable patients; CI = continuous infusion; 5-FU = 5-fluorouracil; NA = not available.
survived. Philip et al [28] used the identical regimen and
achieved a median survival of 7.4 months (table 3). In a
phase III randomized trial, Burris et al. [8] reported a 1-
year survival of 2% in patients receiving 5-FU alone, and
18% with single-agent gemcitabine. In another random-
ized trial [15], 5-FU single-agent treatment induced a 1-
year survival of 9%, while the combined application of 5-
FU and cisplatin yielded a survival rate of 17% (table 4).
Combined treatment with gemcitabine and cisplatin
appears to override the notorious chemoresistance of pan-
creatic cancer, although phase III trials are clearly neces-
sary to determine if this regimen represents a marked pro-
gress of chemotherapeutic efficacy in this rather dismal
patient entity. It remains unclear, however, the extent to
which patient selection contributed to treatment outcome
and the extent to which greater efficacy is achieved at the
expense of quality of life. To answer these questions, ran-
domized studies were initiated comparing single-agent
gemcitabine to gemcitabine/cisplatin. In one such study
by Colucci et al. [29], preliminary results have already
been published. Thirty patients receiving a weekly appli-
cation of gemcitabine 1,000 mg/m2 achieved a response
rate of 10%, while the other 32 patients treated with the
same regimen of gemcitabine and cisplatin at a dose of
25 mg/m2 reached a response rate of 42%. Clinical benefit
responses were 45 and 38%, respectively. Although prom-
ising, the significance of these data is too premature to
assess; moreover, survival data are not yet available.
A German multicenter study comparing gemcitabine
1,000 mg/m2 (day 1, 8, and 15) to cisplatin 50 mg/m2 plus
gemcitabine 1,000 mg/m2 (days 1 and 15), every 28 days,
is currently ongoing.
Combination Therapy with Gemcitabine and
5-Fluorouracil
5-Fluorouracil (5-FU) has been thoroughly investi-
gated as a combination partner for gemcitabine, and a
number of preclinical studies demonstrate synergistic in-
teractions between the two antimetabolites [27]. While
gemcitabine increases 5-FU activity by depletion of cellu-
lar deoxyuridine monophosphate (dUMP) pools and inhi-
bition of thymidylate synthase, 5-FU prevents inactiva-
tion of gemcitabine monophosphate by deamination. 
Five phase I–II studies [7, 30–33] using gemcitabine in
combination with standard doses of 5-FU yielded re-
sponse rates (CR + PR) of 3.7–43% with a median surviv-
al of 7.0–13 months (table 5). One-year survival was
reported in one study [7] and amounted to 22%. Among
studies, however, there was not only a great variability of
evaluable patient numbers, but also considerable varia-
tion among 5-FU applications, which included bolus, 3-
hour, and continuous infusion regimens. It may, there-
fore, not be surprising to find marked differences among
these studies in treatment response and survival.
A further four studies [34–37] evaluated high-dose 5-
FU in various combinations with gemcitabine (table 6).
They achieved response rates of 9.5–19%, and a median
survival of 5.5–8.0 months. A comparison of survival
achieved by gemcitabine in combination with standard-
dose (7–13 months) or high-dose 5-FU (5.5–8 months)
still does not provide evidence for a greater activity of
either regimen (table 4). Clinical benefit response across
all nine studies ranged from 45 to 57%.
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Table 5. Gemcitabine plus standard-dose 5-FU
Reference Phase n/eval Regimen OR, % SD, % Clinical
benefit, %
Survival
months
II 54 5-FU 600 mg/m2, bolus
Gemcitabine 1,000 mg/m2
d 1, 8, 15, q d 29
3.7 63 51 7.0
32 II 24/22 5-FU 600 mg/m2, bolus
Gemcitabine 1,000 mg/m2
d 1, 8, 15, q d 29
12.5 22.4 (69.9*) 7.5
30 II 14 5-FU 500 mg/m2, 3 h
Gemcitabine 1,000 mg/m2
d 1, 8, 15, q d 29
42.8 NA 50 13.0
31 I–II 26 5-FU 200 mg/m2, CI, d 1–29
Gemcitabine 700–1,000 mg/m2**
d 1, 8, 15, q d 29
19.2 42 45 10.3
33 II 15 5-FU 200 mg/m2, CI, d 1–21
Gemcitabine 600 mg/m2
d 1, 8, 15, q d 29
13 40 NA 8.0
* Reported as PS improvement.
** Recommended gemcitabine dose = 900 mg/m2.
n/eval = recruited/evaluable patients; 5-FU = 5-fluorouracil; CI = continuous infusion; OR = overall remission;
SD = stable disease; NA = not available.
Table 6. Gemcitabine plus high-dose 5-FU
Reference Phase n/eval Regimen OR, % SD, % Clinical
benefit, %
Survival
months
I–II 23/21 5-FU 3,000 mg/m2, CI 48h, weekly
Gemcitabine 800–1,400 mg/m2
weekly ! 3, q d 29
19.0 33 57 5.5
35 II 63/48 FA 400 mg/m2, 2 h, d 1
5-FU 400 mg/m2 bolus, d 1
5-FU 2,000–3,000 mg/m2, CI 48 h, d 1–2
Gemcitabine 1,000–1,500 mg/m2, d 3
q 2 weeks
19.1 NA 50 8.0
34 I–II 22/21 Gemcitabine 1,000 mg/m2, d 1
FA 250 mg/m2, 2 h, d 1
5-FU 1,400–2,600 mg/m2, CI 24 h, d 1
weekly ! 3, q d 29
9.5 52 56 NA
36 II 15 Gemcitabine 1,000 mg/m2,
5-FU 2,000 mg/m2, CI 24 h
weekly ! 3, q d 29
14 50 NA 1-year
survival
= 36%
n/eval = Recruited/evaluable patients; FA = folinic acid; 5-FU = 5-fluorouracil; CI = continuous infusion; OR =
overall remission; NA = not available.
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Gemcitabine-Based Four-Drug Regimens
Reni et al. [38] performed a four-drug study including
gemcitabine (600 mg/m2 days 1 and 8), cisplatin (40 mg/
m2 day 1), epirubicin (40 mg/m2 day 1) and continuous
infusion 5-FU (200 mg/m2 days 1–28). In 43 evaluable
stage IV patients, a response rate of 58%, and a median
survival of 9.4+ months (1-year survival = 40+%) were
reported (table 3). Hematologic toxicity was reported with
WHO grade 3–4 neutropenia in 51% and thrombocytope-
nia in 28% of patients. The results of this four-drug regi-
men are highly encouraging and may lead the way to
intensive multi-drug regimens applicable in selected pa-
tients.
An additional trial [39] analyzed combined treatment
with leucovorin (400 mg/m2, day 1), 5-FU bolus (400 mg/
m2, day 1), 5-FU 48-hour continuous infusion (2,000–
2,400 mg/m2, days 1 and 2), followed by gemcitabine
(800 mg/m2, day 3) and oxaliplatin (85 mg/m2, day 3). In
23 patients with advanced pancreatic cancer (n = 14) and
cancer of unknown primary (n = 9), a response rate of
35% was observed. In the group of pancreatic cancer
patients, 2 CRs, 2 PRs, a median progression-free surviv-
al of 8 months, and a median survival of 9 months were
reported.
Gemcitabine Combined with Irinotecan or
Docetaxel: Preliminary Data
Results of preliminary studies evaluating the clinical
impact of irinotecan (CPT-11) or docetaxel in combina-
tion with gemcitabine in patients with pancreatic cancer
have recently been reported. 
Two phase II, multicenter studies of irinotecan, a
topoisomerase inhibitor, plus gemcitabine in chemonaive
patients with locally advanced and metastatic pancreatic
cancer have demonstrated response rates of 20% (45 eva-
luable patients) and 15% (20 evaluable patients), respec-
tively [40, 41]. Both studies used the same 3-week sched-
ule, but the former administered irinotecan 100 mg/m2
and gemcitabine 1,000 mg/m2 on both days 1 and 8, while
the latter administered a higher dose of irinotecan,
300 mg/m2, on day 8 only with gemcitabine 900 mg/m2 on
days 1 and 8. Both regimens were considered well tolerat-
ed and relatively active with possibilities for further phase
III study.
Based on promising phase II data [40], Rocha Lima
and colleagues have initiated a randomized multicenter
phase III trial (MUSC 8982) comparing the combination
of irinotecan 100 mg/m2 (days 1 and 8), plus gemcitabine
1,000 mg/m2 (days 1 and 8), every 21 days; with gemcita-
bine 1,000 mg/m2 (weekly ! 7 for the 1st cycle, then days
1, 8, and 15), every 28 days. The primary endpoint is sur-
vival, with secondary measures of objective response,
CA19-9, time to treatment failure, safety, PS, weight loss,
albumin, and quality of life. Target accrual is 350 patients
(175 per study arm) at a rate of 20 per month; follow-up
will be 12 months. The investigators have accrued 60
patients, and seek a 2-month difference in median surviv-
al (Rocha Lima, personal communication).
In a phase I study, maximum tolerated dose study of
escalating dose levels of docetaxel (25–40 mg/m2) and
gemcitabine (800 or 1,000 mg/m2) in 25 chemonaive
patients with locally advanced or metastatic pancreatic
carcinoma, the recommended dose level was established
at gemcitabine 1,000 mg/m2 plus docetaxel 35 mg/m2
administered weekly at 3-week intervals [42]. Dose-limit-
ing toxicities included WHO grades 3 and 4 gastrointesti-
nal toxicity and leukopenia. Preliminary efficacy results
in the phase II ongoing study are encouraging with a 23%
objective response rate and disease stabilization rate of
69% in 13 patients included thus far. 
A phase I/II study in pancreatic cancer evaluated two
regimens of gemcitabine and docetaxel: gemcitabine
800 mg/m2 on days 1, 8 and 15 and docetaxel 75 mg/m2
on day 1 of a 28-day schedule (Group A, n = 18), and
gemcitabine 1,000 mg/m2 and docetaxel 40 mg/m2 on
days 1 and 8 on a 21-day schedule (Group B, n = 11) [43].
The former schedule (A) was changed due to excessive
hematologic toxicity requiring a dose reduction in 13
patients. (Schedule B, days 1 and 8 every 21 days, is the
recommended regimen [Jacobs, pers. commun.]) Of the
25 patients evaluable for response, 7 (28%) achieved a PR
and 10 (40%) either a minor response or stable disease.
Sites of response were pancreas, peritoneum, lung, skin,
and liver. Median time to progression was 5.25 months.
The regimen in Group B was better tolerated with only
two patients with hematologic toxicity (grade 2) versus 13
patients (grades 2/3) in Group A. The authors concluded
that the response and survival data were encouraging giv-
en the poor prognosis for this cancer and the few palliative
choices available. 
In another phase II study in which all patients had met-
astatic disease, gemcitabine 600 mg/m2 on days 1, 8, and
15 plus docetaxel 60 mg/m2 on day 1 over 28-day cycles
yielded an overall response rate of 8% (2/24 patients)
including one CR [44]. However, an additional 4 of 7
patients with SD after four cycles had a greater than 75%
reduction in CA 19-9 titer.
MUSC 8982
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Table 7. Ongoing gemcitabine studies in
pancreatic cancer Study Design Chemotherapy Investigator
Randomized
Phase III
Gem + CPT-11 vs. gem Rocha Lima
CALGB 89805 Phase II Gem + radiation Blackstock/Tempero
CALGB 89904 Randomized
Phase II
Gem + cis; gem + doc;
gem + CPT-11;
high-dose single-agent gem
Kulke, Tempero
ECOG E-1298 Phase II Gem + doc Shepard
NCCTG 964352 Phase I Gem + cis + radiation Not available
CALGB = Cancer and Leukemia Group B; cis = cisplatin; CPT-11 = irinotecan; doc =
docetaxel; ECOG = Eastern Cooperative Oncology Group; gem = gemcitabine; MUSC =
Medical University of South Carolina; NCCTG = North Central Cancer Treatment Group.
Gemcitabine and Matrix Metalloprotease
Inhibitors
Matrix metalloproteases (MMPs) represent a group of
zinc-dependent enzymes involved in remodelling and
turnover of extracellular matrix proteins, play a role in
wound healing, and are involved in the pathogenesis of
arthritis. Because MMPs are related to the tumor’s ability
to metastasize and the in the process of angiogenesis, high
expression of MMPs is associated with cancer malignan-
cy. Treatment with MMP inhibitors (MMPIs) alone or in
combination with cytotoxic therapy is a novel approach
in the control of tumor progression and, thus, the manage-
ment of malignancies. Based on promising preclinical
studies, synthetic MMPIs, such as marimastat, BAY
129566, CGS-27023A, prinomastat (AG-3340), BMS-
275291, and metastat (COL-3), have been developed and
included in clinical trials [45]. These drugs are involved at
all stages of clinical drug development. The MMPIs have
been evaluated as single agents, as well as in combination
with other chemotherapeutic agents with the objective of
reducing the size and number of metastatic lesions.
To determine whether MMPIs are capable of poten-
tiating the effects of chemotherapy, various phase I trials
were initiated to examine the safety of concomitant treat-
ment. In a phase I study of the combination of gemcita-
bine and marimastat as first-line therapy [46], sequential
marimastat doses of 5, 10, 15, and 20 mg BID were evalu-
ated in 31 patients. Gemcitabine was administered at a
dose of 1,000 mg/m2 weekly for 3 of 4 weeks. Six patients
experienced significant musculoskeletal toxicity related to
marimastat therapy. Other toxicities included grade 4 ele-
vated bilirubin, myelopsuppression, abnormal liver func-
tion tests, and back pain; the remaining toxicities were
mild. Of the 11 evaluable patients, response was detected
in 2 patients and stable disease in 6 patients. Sustained
declines in CA19-9 were recorded in 9 patients. The
authors concluded that marimastat, when combined with
gemcitabine, did not appear to increase the incidence or
severity of chemotherapy-related adverse events.
A number of phase III clinical trials comparing gemci-
tabine to MMPIs are ongoing, but only one, conducted by
Rosemurgy et al., has been reported thus far [47, 48]. This
study compared gemcitabine to marimastat as first-line
therapy in 414 patients with unresectable pancreatic can-
cer. Patients were randomized to marimastat (5, 10, or
25 mg BID) or gemcitabine 1,000 mg/m2 weekly for 7 of 8
weeks and then weekly for 3 of 4 weeks until the occur-
rence of disease progression or toxicity. With the study
designed to detect a 16% or greater reduction in mortality,
no statistically significant differences between gemcita-
bine and the three doses of marimastat were found in
terms of the primary endpoint of overall survival. Safety
data revealed no marked differences between the treat-
ment groups other than the expected side effects of mus-
culoskeletal toxicity with marimastat and the hematologic
toxicity with gemcitabine.
Future Directions
A number of ongoing studies in advanced metastatic
and/or locally advanced pancreatic cancer utilizing gem-
citabine in combination with other agents is summarized
in table 7.
Gemcitabine in the Treatment of Pancreatic
Cancer
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Conclusions
Gemcitabine has been successfully introduced as a
well-tolerated agent in the treatment of pancreatic cancer,
and is presently recommended as the standard of care for
first-line treatment of pancreatic cancer. The activity
observed with the combination of gemcitabine with cis-
platin or 5-FU appears promising (table 6), although its
superiority to single-agent treatment regarding response
rates and survival needs to be confirmed in randomized,
phase III trials, which are ongoing or completed but not
yet published. Randomized trials comparing single-agent
gemcitabine to combination treatment are presently on-
going. Gemcitabine-based four-drug regimens promise a
further increase of efficacy, but confirmatory trials are
needed. Preliminary data from the recent coupling of
gemcitabine with irinotecan, docetaxel, or MMPIs offer
another encouraging alternative for pancreatic cancer.
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